Page 6,546«..1020..6,5456,5466,5476,548..6,5606,570..»

FDA, UCSF Partnership Helps Industry Identify Drug Interactions

Posted: Published on September 5th, 2012

UCSF's Kathleen Giacomini, PhD, a leader in the study of pharmacogenomics how an individuals genetics determine his or her response to medicines, is partnering with the Food and Drug Administration on a project to identify drug interactions before the medicines reach patients. Drug interactions and drug side effects occur all-too-often in patients lives. Now theres a new online resource to help guide pharmaceutical developers as they endeavor to improve testing for potentially harmful drug interactions before new medicines reach consumers. The UCSF-FDA TransPortal is the result of partnership spearheaded by UCSF and the U.S Food and Drug Administration (FDA). Its focus is on how drugs interact with gatekeeper proteins called membrane transporters. Transporters play specific roles as hosts or bouncers to either boot out specific drugs or to escort them inside. They control whether drugs can gain access to cells and organs throughout the body, including the liver and kidneys big players in drug metabolism and elimination. In recent years specific transporters have been found to play a role in drug side effects, such as the muscle pain and weakness sometimes caused by statins. Transporters influence the effectiveness of certain anti-cancer treatments. An unanticipated drug interaction with a transporter associated … Continue reading →

Posted in Drug Side Effects | Comments Off on FDA, UCSF Partnership Helps Industry Identify Drug Interactions

NIH Funds UCLA Phase 2 Study of MediciNova's MN-166 in Treating Drug Addiction

Posted: Published on September 5th, 2012

LOS ANGELES and SAN DIEGO, Sept. 4, 2012 (GLOBE NEWSWIRE) -- The University of California, Los Angeles' (UCLA's) Department of Family Medicine/Center for Behavioral and Addiction Medicine, and MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced approval and funding by the National Institutes on Drug Abuse (NIDA), part of the National Institutes of Health, of a Phase 2 clinical trial studying the use of MN-166 (ibudilast) for the treatment of methamphetamine addiction. Building on an ongoing UCLA MN-166 Phase 1b safety trial, NIDA has now awarded grant funding for a statistically powered Phase 2 outpatient study in methamphetamine addicts. MediciNova will provide drug supply and regulatory support for the Phase 2 trial. "UCLA has long recognized the danger of methamphetamine abuse, and NIDA has actively supported our research on understanding methamphetamine's effects on the brain and behavior in order to develop prevention and treatment strategies, including medications," said Steven Shoptaw, Ph.D., Professor, UCLA Departments of Family Medicine and Psychiatry and Biobehavioral Sciences. "Methamphetamine addiction is a tremendous societal burden and also contributes to healthcare costs from premature conditions such as heart attacks … Continue reading →

Posted in Drug Dependency | Comments Off on NIH Funds UCLA Phase 2 Study of MediciNova's MN-166 in Treating Drug Addiction

Job applicants fail drug testing

Posted: Published on September 5th, 2012

The directors of The Employment Source and the Tuscarawas County Chamber of Commerce say they are concerned about a growing trend: Individuals unable to enter the job market because they cant pass initial drug screenings. Its a real frustration for local companies because of the large number of applicants that fail a drug screening, said Scott Robinson, president and chief executive officer of the Tuscarawas County Chamber of Commerce. Local companies have brought the issue to his attention, Robinson said. Now, The Employment Source and the chamber, along with other organizations, are working together to conduct a survey to identify work force needs in the county. Robinson said they hope to learn exactly how much drugs and alcohol are interfering with the county work force. Liz Carter runs Elizabeth Carter Consulting, based in New Concord. She specializes in training in the oil and gas industry. A former human resources coordinator for a large oil and gas company, Carter said there is a problem. Based on my personal experience, I would say that at least one out of 15 potential employees would test positive for pre-employment drug testing. However, most employees are aware that they will have to test for a … Continue reading →

Posted in Drug Dependency | Comments Off on Job applicants fail drug testing

Activists Come To Chicago To Protest War On Drugs

Posted: Published on September 5th, 2012

Ald. Roberto Maldonado (26th) addresses reporters at a news conference by the Caravan for Peace with Justice and Dignity, which has come to Chicago to protest the War on Drugs. (Credit: CBS) CHICAGO (CBS) Activists are in Chicago Tuesday to voice their opposition to the War on Drugs. As WBBM Newsradios Brandis Friedman reports, the Caravan for Peace with Justice and Dignity is making its way from San Diego to Washington, D.C., spreading its message. LISTEN: WBBM Newsradios Brandis Friedman reports That message, as heard Tuesday in a news conference at City Hall, is, Drugs are bad, but the War on Drugs is worse. The group of Mexican and American nationals says the decades-old War on Drugs compares to alcohol prohibition in the 1920s, and pointed out that Prohibition turned Chicago into a hub of Mafia crime at the time. Among the participants in the caravan was Javier Sicilia, whose son was murdered along with six others in March 2011. He spoke through an interpreter, Eighty years later, despite Prohibition, this phenomenon has been reproduced but even more brutally, and on an international scale. The caravan has support from the group Law Enforcement Against Prohibition, which argues for decriminalizing drugs … Continue reading →

Posted in Drugs | Comments Off on Activists Come To Chicago To Protest War On Drugs

Patient tests pick best depression drugs

Posted: Published on September 5th, 2012

People with depression often cycle through several drugs before they find one that helps. Now, at least three companies say they can improve the odds that patients get the right therapy quickly. CNS Response, AssureRx Health and Brain Resource are offering new tests designed to find physical and mental patterns that will predict the best treatment for individual patients. In doing so, they are also creating a new testing market that CNS Chief Executive Officer George Carpenter said may reach $2.7 billion a year in the United States. Because there's no one cause for depression, a disorder that can overwhelm its victims with feelings of sadness, frustration and anger, no single medicine works the same for each patient. That can mean months of experimenting before treatment takes hold, an added burden for people already trying to maintain work and personal relationships. Prescribing the right drug is "something we've struggled with for a long time," said Philip Muskin, a professor of clinical psychiatry at Columbia University in New York. "There are no hard criteria to say, use Prozac or Zoloft or any of the other famous antidepressants." About 15.5 million people reported struggling with bouts of depression in a 2010 U.S. … Continue reading →

Posted in Drugs | Comments Off on Patient tests pick best depression drugs

Research and Markets: Global Ovarian Cancer Drugs Market 2011-2015: Patent Expiration of Key Drugs Could Pose a …

Posted: Published on September 5th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/gh388z/global_ovarian_can) has announced the addition of the "Global Ovarian Cancer Drugs Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of ovarian cancer. The Global Ovarian Cancer Drugs market has also been witnessing the trend of the use of combination therapies for the treatment of ovarian cancer. Commenting on the report, an analyst from TechNavio's Healthcare team said; ''The current trend witnessed by the Global Ovarian Cancer Drugs market is the use of combination therapies for the treatment of ovarian cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and the destruction of cancerous cells. The combination is chosen according to the size of the tumor and the risk of recurrence.'' According to the … Continue reading →

Posted in Drugs | Comments Off on Research and Markets: Global Ovarian Cancer Drugs Market 2011-2015: Patent Expiration of Key Drugs Could Pose a …

Canton pharmacy break-ins linked to group of thieves

Posted: Published on September 5th, 2012

A string of at least five pharmacy break-ins in Canton this summer have been committed by at least two crews of thieves, police said this morning. Police released surveillance images of several burglars today and are hoping someone will recognize them or their vehicles. According to police, the burglaries which started July 4 are primarily taking place between midnight and 5 a.m. The thieves usually break out a window on the door and spend just a few minutes in the store. Police said some of the thefts have been committed by two white men and others have been committed by two black men. In the most recent case, which was reported Aug. 24, two white men and two black men were seen in surveillance images, police said. The two white men appeared to be driving a light-colored, four-door, mid-sized sedan possibly either a Pontiac G6 or Dodge Neon. In all the cases, the thieves have taken measures to conceal their identities, including wearing ski masks, bandanas and baseball caps. The Canton Police Department is asking anyone with information to call 734-394-5400 or Crime Stoppers at 1-800-SPEAK-UP. A cash reward of up to $1,000 is being offered through Crime Stoppers. Follow … Continue reading →

Posted in Pharmacy | Comments Off on Canton pharmacy break-ins linked to group of thieves

Convicted Murderer In OKC Pharmacy Shooting Death Out Of Jail

Posted: Published on September 5th, 2012

OKLAHOMA CITY - A convicted murderer in an Oklahoma City pharmacy shooting death is out of prison. 4/26/2011 Related Story: Testimony Begins In Trial Of OKC Pharmacy Murder Suspects Jevontai Ingram is one of two masked robbers who held up Jerome Ersland at the Reliable Pharmacy back in 2009. Like Ersland, Ingram is convicted of murder. Jevontai Ingram spent less than four years in custody after pleading guilty to murder for his role in the death of his accomplice. Ingram was 14 when Pharmacist Jerome Ersland shot and killed Ingram's accomplice during an attempted robbery. Ingram's testimony about what happened helped get him a deal with the state. At the time of the shooting, the state considered Ingram a youthful offender. Now Ingram is an adult, at the age of 18, he is making plans for the future despite his confession to murder and conspiracy to rob the pharmacy. Ingram served three years because his accomplice, Antwun Parker, died during their robbery attempt. Ingram does not agree with the amount of time he was made to serve, and his attorney confirmed he has "no mercy" for Jerome Ersland, the pharmacist also serving time for murder. "If he thinks Jerome needs … Continue reading →

Posted in Pharmacy | Comments Off on Convicted Murderer In OKC Pharmacy Shooting Death Out Of Jail

Eaton Scientific Enters Agreement with RoxSan Pharmacy to Provide Tropine 3 for its upcoming Clinical Trial Participants

Posted: Published on September 5th, 2012

BEVERLY HILLS, Calif., Sept. 4, 2012 /PRNewswire/ --Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (PRTN) is pleased to announce that the Company has entered into an agreement with RoxSan Pharmacy Inc. to provide continued specialized compound prescription of Homatropine in a novel oral suspension ("Tropine 3") to support planned FDA compliant Clinical trial participants. Tropine 3 is a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women. Details regarding the multi-location multi-phase FDA compliant Tropine 3 clinic trials are expected to be finalized within the next few weeks. "We feel that the RoxSan Pharmacy team and facilities are uniquely qualified to continually supply the Clinical Trial with the highest-quality custom dosage of and support during our planned FDA compliant clinical trials period that is excepted to dramatically increase localized demand," stated Michael Borkowski, CEO and President of Eaton Scientific. RoxSan Pharmacy has over 40 years of experience with a highly-qualified and educated team of pharmacists, technicians, and chemists to custom prepare high-quality compounded and manufactured medications using several unique delivery systems including, but not limited to, … Continue reading →

Posted in Pharmacy | Comments Off on Eaton Scientific Enters Agreement with RoxSan Pharmacy to Provide Tropine 3 for its upcoming Clinical Trial Participants

AlloCure Begins Phase 2 Clinical Trial in Acute Kidney Injury

Posted: Published on September 5th, 2012

BURLINGTON, Mass.--(BUSINESS WIRE)-- AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the companys mesenchymal stem cell therapy, as a potential treatment for acute kidney injury (AKI). The randomized, double-blind, placebo-controlled, multi-center trial, designated ACT-AKI (AC607 Trial in Acute Kidney Injury) (NCT01602328), will enroll 200 cardiac surgery subjects at leading tertiary care centers in the United States. ACT-AKI follows the positive results from a phase 1 AC607 trial in cardiac surgery subjects, which showed an excellent safety profile and encouraging data on the incidence of AKI and hospital length of stay, said Robert M. Brenner, M.D., AlloCure President and Chief Executive Officer. We have worked closely with leaders in the field on the design of ACT-AKI, and trial initiation represents an important milestone for AlloCure and the patients we collectively serve. AC607 is a promising therapeutic candidate for AKI, for which effective therapies are greatly needed, said Richard J. Glassock, M.D., Emeritus Professor of Medicine at the Geffen School of Medicine at the University of California, Los Angeles. The initiation of ACT-AKI represents a critical step in the development of an innovative therapy for this all-too-common, serious and costly medical condition, for which no … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on AlloCure Begins Phase 2 Clinical Trial in Acute Kidney Injury

Page 6,546«..1020..6,5456,5466,5476,548..6,5606,570..»